File Download
  Patent History
  • Application
    EP 20100791704 2010-06-21
  • Publication
    EP 2445859 2012-05-02

published patent: METHOD FOR ISOLATING CIMIRACEMATE A

TitleMETHOD FOR ISOLATING CIMIRACEMATE A
Priority Date2010-06-21 PCT/IB2010001772
2009-06-21 US 12/218962P
Inventors
Issue Date30-Nov-2012
Citation
EP Published Patent application EP 2445859. European Patent Office (EPO), Escapenet, 2012 How to Cite?
AbstractThe subject invention provides a method for optimal isolation of cimiracemate A for subsequent use as a therapeutic agent or dietary supplement in single entry or in combination with other treatment modalities. In addition, the subject invention discloses cimiracemate A as a bioactive marker that can be used to identify the members of the Cimicifuga genus for example: C. racemosa, C. dahitrica (Turcz.) Maxim., C. foetida L., and C. heracleifolia Kom. The bioactive marker cimiracemate A can also be used to standardize the extracts of C. racemosa as anti-inflammatory agents for the treatment of inflammatory conditions associated with diseases and syndromes including, for example, rheumatism, stroke, myocarditis, atherosclerosis, infectious diseases, allergy and related autoimmune diseases.
Persistent Identifierhttp://hdl.handle.net/10722/176770

 

DC FieldValueLanguage
dc.date.accessioned2012-11-30T08:38:27Z-
dc.date.available2012-11-30T08:38:27Z-
dc.date.issued2012-11-30-
dc.identifier.citationEP Published Patent application EP 2445859. European Patent Office (EPO), Escapenet, 2012en_HK
dc.identifier.urihttp://hdl.handle.net/10722/176770-
dc.description.abstractThe subject invention provides a method for optimal isolation of cimiracemate A for subsequent use as a therapeutic agent or dietary supplement in single entry or in combination with other treatment modalities. In addition, the subject invention discloses cimiracemate A as a bioactive marker that can be used to identify the members of the Cimicifuga genus for example: C. racemosa, C. dahitrica (Turcz.) Maxim., C. foetida L., and C. heracleifolia Kom. The bioactive marker cimiracemate A can also be used to standardize the extracts of C. racemosa as anti-inflammatory agents for the treatment of inflammatory conditions associated with diseases and syndromes including, for example, rheumatism, stroke, myocarditis, atherosclerosis, infectious diseases, allergy and related autoimmune diseases.en_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License For Public Patent Documentsen_US
dc.titleMETHOD FOR ISOLATING CIMIRACEMATE Aen_HK
dc.typePatenten_US
dc.description.naturepublished_or_final_versionen_US
dc.contributor.inventorYang, Lai Hung, Cindyen_HK
dc.contributor.inventorLau, ASYen_HK
patents.identifier.applicationEP 20100791704en_HK
patents.description.assigneePURAPHARM INTERNAT HK LTD [CN]; VERSITECH LTD [CN] en_HK
patents.description.countryEuropean Patent Office en_HK
patents.date.publication2012-05-02en_HK
patents.date.application2010-06-21en_HK
patents.date.priority2010-06-21 PCT/IB2010001772en_HK
patents.date.priority2009-06-21 US 12/218962Pen_HK
patents.description.ccEPen_HK
patents.identifier.publicationEP 2445859en_HK
patents.relation.familyAU 2010264200 (A1) 2012-01-19en_HK
patents.relation.familyCA 2766002 (A1) 2010-12-29en_HK
patents.relation.familyCN 102625791 (A) 2012-08-01en_HK
patents.relation.familyEP 2445859 (A2) 2012-05-02en_HK
patents.relation.familyUS 2012190882 (A1) 2012-07-26en_HK
patents.relation.familyWO 2010150102 (A2) 2010-12-29 en_HK
patents.description.kindA2en_HK
patents.typePatent_publisheden_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats